R. Wooster

发表

Subtype and pathway specific responses to anticancer compounds in breast cancer

Joshua M. Stuart, Laura M. Heiser, Nicholas J. Wang, 2011, Proceedings of the National Academy of Sciences.

Molecular target class is predictive of in vitro response profile.

Joel Greshock, Richard Wooster, J. Greshock, 2010, Cancer research.

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

Joel Greshock, Nancy Liu-Sullivan, Richard Wooster, 2010, Molecular Cancer Therapeutics.

Analysis of glutamine dependency in non-small cell lung cancer

K. Bachman, R. Wooster, A. V. D. van den Heuvel, 2012, Cancer biology & therapy.

Tumor-stroma relationships

R. Wooster, 2012, Cell cycle.

99 POSTER Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation

B. Weber, J. Greshock, R. Wooster, 2008 .

Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors

R. Wooster, Sara Movassaghian, M. Bilodeau, 2020, Molecular Cancer Therapeutics.

Combined Phosphatase and Tensin Homolog (PTEN) Loss and Fatty Acid Synthase (FAS) Overexpression Worsens the Prognosis of Chinese Patients with Hepatocellular Carcinoma

Jiuhong Kang, J. Greshock, K. Bachman, 2012, International journal of molecular sciences.

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer

Laura M. Heiser, Nicholas J. Wang, P. Spellman, 2016, Breast Cancer Research.

Targeted quantitation of CFTR protein expression in vivo using immunoprecipitation & parallel reaction monitoring tandem mass spectrometry

R. Wooster, Gan Sun, Yunxiang Dai, 2022, Translational Medicine Communications.

Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

R. Wooster, R. Alargova, A. Brockman, 2019, Molecular Cancer Therapeutics.

The clinical progress of mRNA vaccines and immunotherapies

Daniel G. Anderson, R. Wooster, P. Zhang, 2022, Nature Biotechnology.

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.

R. Wooster, R. Alargova, A. Brockman, 2019, Journal of medicinal chemistry.

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Experimental Therapeutics, Molecular Targets, and Chemical Biology

K. Yamaguchi, J. Greshock, R. Wooster, 2009 .

Abstract 3674: Pentarins: Improved tumor targeting through nanoparticle encapsulation of miniaturized biologic drug conjugates

D. Rockwood, R. Wooster, S. Kadiyala, 2015 .

Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia.

R. Wooster, C. Woo, M. Thamsen, 2022, Pulmonary pharmacology & therapeutics.

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Neysa Nevins, W. D. Cornwell, R. Annan, 2010, Proceedings of the National Academy of Sciences.

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells

Jennifer B Dennison, G. Mills, J. Briand, 2013, Cancer & Metabolism.

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells

Jennifer B Dennison, G. Mills, J. Briand, 2013, Cancer & metabolism.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network

S. Vowler, I. Mills, D. Neal, 2014, EMBO molecular medicine.

Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.

Zhe Zhang, B. Weber, E. Rappaport, 2010, Cancer research.

Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

J. Maris, S. Diskin, R. Wooster, 2013, International journal of cancer.

Integrated analysis of breast cancer cell lines reveals unique signaling pathways

Zhi Hu, Merrill Knapp, Laura M. Heiser, 2009, Genome Biology.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

K. Yamaguchi, J. Greshock, R. Wooster, 2009, Cancer research.

Systematic analysis of genotype‐specific drug responses in cancer

Yiling Lu, Gordon B Mills, Fan Zhang, 2012, International journal of cancer.

Preclinical Development Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK 1120212

J. Holbrook, J. Greshock, K. Bachman, 2012 .

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

J. Holbrook, J. Greshock, K. Bachman, 2011, Molecular Cancer Therapeutics.

Sequence variants of the axin gene in breast, colon, and other cancers: An analysis of mutations that interfere with GSK3 binding

T. Dale, R. Wooster, E. Sara, 2000, Genes, chromosomes & cancer.

Mutation and copy number detection in human cancers using a custom genotyping assay.

J. Greshock, K. Bachman, R. Wooster, 2011, Genomics.

High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916

Ramona N Plant, J. Greshock, K. Bachman, 2011, Journal of Translational Medicine.

Abstract 39: Discovery of PEN-221, an SSTR2-targeting maytansinoid conjugate with potent activity in vitro and in vivo

R. Wooster, M. Simcox, R. Alargova, 2017 .

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer

Mark A. Dane, Laura M. Heiser, Nicholas J. Wang, 2017, Breast Cancer Research.

Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)

S. Powers, R. Wooster, Jianping Zhang, 2011, Oncotarget.

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

R. Wooster, P. Workman, R. Wooster, 2001, Biochemical pharmacology.

Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling

R. Wooster, C. Fisher, J. Clark, 2003, British Journal of Cancer.

Effect of Predictive Performance of a Biomarker for the Sample Size of Targeted Designs for Randomized Clinical Trials

Xiwu Lin, J. Greshock, R. Wooster, 2011 .

Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency

J. Greshock, M. A. Hardwicke, R. Wooster, 2012 .